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Introduction 
Breast cancer is the most common cancer in women (37, 52). Starting in 2005, a 
systematic population-based Mammography Screening Program was successfully 
introduced in Germany – “Mammography Screening 1.0”. Women from 50-69 years 
of age are currently invited for screening (2, 30). The aim is to detect breast cancer 
early, to accelerate access to treatment options, and ultimately reduce mortality (26, 
35, 42, 73). However, there is still ongoing debate about the optimal age to initiate 
screening, the most efficient intervals between mammograms, and the degree of 
harmful effects (10, 73). Over diagnosis and exposure to radiation is an emerging 
concern for breast cancer screening (26, 35, 42, 73). Screening recommendations 
for breast cancer in the general population are currently based solely on the age 
and gender of an individual, despite the fact that apart from age additional genetic 
and non-genetic factors are known to influence cancer risk (54).  
There are already target groups in Germany, for which risk-adapted screening has 
been implemented (40). Currently women who fulfill the inclusion criteria for the 
German Consortium for Hereditary Breast and Ovarian Cancer, and who carry a 
mutation in a known cancer gene, have access to an intensified surveillance 
program. The crucial point is the detection of a high risk gene (BRCA1, BRCA2, 
CDH1 or TP53) or a moderate gene (CHEK2, PALB2, RAD51C/D, NBN or ATM) (59). 
Another target group are women who were treated for Hodgkin´s disease (HD) in 
childhood or adolescence and who have an increased risk to develop breast cancer 
due to prior radiotherapy. These women also have access to an intensified 
surveillance program (58). Families who fulfill the inclusion criteria for the German 
Consortium for Hereditary Breast and Ovarian Cancer, where no mutation in any 
known risk gene can be identified, are more challenging. In this constellation, the 
decision to recommend intensified surveillance is based on the calculated risk 
(heterozygous risk > 20% or lifetime risk > 30%) based on Cyrillic (40). 
However, for the general population only the woman´s age is taken into account for 
participation to the Mammography Screening Program 1.0 whereas other risk factors 
influence the disease risk (54). The current program therefore does not meet an 
individuals different needs for screening. In many women, mammography is 
performed without clear benefit. Other women, especially younger women, are not 
included in the program despite the presence of risk factors (19). Apart from familial 
predisposition, the time of menarche and menopause plays a part, for example, and 
also hormone replacement therapy and life style. More recent risk models take some 
of these factors into account (53, 54, 67). They would allow for the implication of a 
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risk adapted screening approach “Mammography Screening 2.0” (18). On one hand 
there is a need to avoid unnecessary diagnostic procedures involving radiation in 
women who are unlikely to develop breast cancer, on the other hand there is a need 
to intensify diagnostic procedures for women at high risk. The aim of Mammography 
Screening 2.0 is to improve the efficiency of the screening program and to help guide 
screening decisions by applying individual risk profiles and preferences (14). 
However, the implementation of such a strategy faces new challenges, such as the 
choice of the adequate prediction model, the interpretation of the results, and the 
ways to communicate the risks. My research focuses on the question whether we 
can overcome the difficulties that may arise with implementation of Mammography 
Screening 2.0. 
Breast cancer – a future cancer burden 
Breast cancer is one of the most important public health concerns, as it is worldwide 
the most common cancer, and the most common cause of cancer death, among 
women (25). The incidence of breast cancer has risen in the last decades due to 
changes in lifestyle, reproduction, and diet. Because of demographic ageing, it will 
be an even more important public health concern in the future (57).  
 
 
In our research group we project the cancer incidence case number as well as the 
number of deaths for the most common cancer – including breast cancer – in 
Germany (52). For this study, cancer registry data from the Robert Koch Institute 
(RKI) (75) and demographic projections from the Federal Statistical Office of 
Germany were used (63). We projected incidences in 2020 and 2030, based on 
changing demographics and the change in average annual percent changes (AAPC) 
for the 14 most common cancer sites in women, men, and combined for both sexes 
(Figure1, left). Further we also projected cancer-related deaths (Figure1, right).  
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Figure 1: The formulas were used to project cancer incidences (left) and cancer-related deaths (right) (52). 
With regard to breast cancer, we could show that among women, it is projected to 
remain the most common malignancy with constant increase in case numbers over 
the next two decades (Figure 2A) (52). The good news is that the absolute number 
of projected cancer deaths is projected to decline over the next two decades (Figure 
2A). Early detection as well as improved management has led to an improvement of 
prognosis of women suffering from breast cancer (1). However, breast cancer still 
remains the second leading cause of cancer death in women (Figure 2B) (52). 
 
A       B 
 
Figure 2: (A) Top five projected incident cases in Germany by 2020 and 2030, among women. (B) Top five 
projected cancer death numbers in Germany by 2020 and 2030, among women. (52) 
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Breast Cancer Risk Assessment 
A basic requirement for individualized screening is an accurate assessment of a 
woman´s cancer risk. In the United States of America (USA), annual screening 
mammography and magnetic resonance imaging (MRI), beginning at 30 years of 
age, are recommended for women with a lifetime risk of 20% or greater (61). Thus, 
a statistical tool is needed to estimate the probability that a currently healthy women 
with specific risk factors (e.g. family history) will develop breast cancer within a 
certain time period (such as within ten years or in a lifetime) (22, 23).  
Various statistical models have been developed for assigning absolute risks of 
developing breast cancer (5, 21, 47, 67). Nevertheless, the models differ in regard 
to the considered risk factors and how competing risks of death are being handled. 
More specifically, the different models can be divided into two main categories: 
empiric models and genetic models (55). Empiric models are based on results of 
epidemiological studies. Variables that are statistically significant and have a large 
magnitude of effect are chosen and combined using logistic regression to produce 
risk estimates (9). Genetic models use pedigree analysis in the form of Bayesian 
analysis which are based on comprehensive family history e.g. age at cancer 
diagnosis (9). Consequently, they can yield substantially different risk estimates. 
Therefore, the choice of a particular prediction model is an important aspect of 
individualized screening and surveillance (23).  
In the two studies we have compared the performance of commonly used breast 
cancer risk prediction models with respect to calibration, discrimination and 
accuracy of very commonly used risk prediction models, focusing on different 
aspects: 
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In this study, we evaluated two commonly used risk prediction models the Breast 
Cancer Risk Assessment Tool (BCRAT) (20, 21) and the International Breast Cancer 
Intervention Study (IBIS) (67) risk assessment tool in a longitudinal New York City 
(NYC) cohort (n=1857) (54). The BCRAT is the most frequently used model in the 
USA, e.g. to determine whether a woman meets the minimum risk threshold of a 
five-year risk of at least 1.67% for considering tamoxifen for chemoprevention (17). 
The BCRAT model is an empiric model including current age, age at menarche, age 
at first live birth, number of previous biopsies, history of atypical hyperplasia, 
race/ethnicity, and number of affected first-degree relatives (15, 20, 21, 44). In 
contrast, the IBIS model is a genetic model including extended family history, 
BRCA1/2 genetic status with non genetic risk factors such as age, age at menarche, 
parity, age at first live birth, age at menopause, history of hormone replacement 
therapy (HRT) use, history of hyperplasia/atypical hyperplasia, history of lobular 
carcinoma in situ, height, and body mass index (BMI) (67).  
It is well known that the short-term and lifetime breast cancer risks assigned to a 
woman by BCRA and IBIS models vary considerably. Figure 3 shows weak 
correlation (r=0.34) between the lifetime risks assigned by BCRAT model and IBIS 
model to the 1,857 participants in the current study. The IBIS model tends to assign 
lower risks than the IBIS model to women with a strong family history of breast 
cancer than does the IBIS model (54). 
 
Figure 3: Scatterplot of BRCAT and IBIS lifetime risks. The horizontal and vertical coordinates of points give the 
1857 subjects’ lifetime risks as assigned by BCRAT and IBIS, respectively. The two sets of assigned risks are 
only weakly correlated (Pearson correlation coefficient r=0.34) (54). 
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Consequently, clinicians typically use models like BCRAT for women with average 
risk and models like IBIS for women with above average risk. However, the objective 
of this study was to compare model performance in subgroups of women typically 
thought to be of average risk versus subgroups classified as above average risk of 
breast cancer. We assessed model calibration to compare how well the model 
predictions agree with outcome prevalences within subgroups of the population 
(measurement: Hosmer Lemeshow goodness of fit statistics) (34) and we assessed 
the discrimination to compare its ability to discriminate those with different true risks 
(measurement: area under the receiver operating characteristic (ROC) curve) (29). 
Figure 4 shows that overall, the agreement between assigned and observed risk was 
better for IBIS (HL X42=7.2 P value 0.13) than BCRAT (HL X42=22.0 P value <0.001). 
The IBIS model also showed better discrimination (AUC=69,5%, CI=63,8% to 75,2%) 
than the BRCAT model (AUC=63,2%, CI=57,6% to 68,9%) (54). 
 
Figure 4: Calibration of BRCAT and IBIS models. The horizontal coordinates of points represent the mean 10-
year assigned risks of BCRAT (left panel) and IBIS (right panel) within quartiles of assigned risk. Vertical 
coordinates represent quartile-specific estimates of 10-year breast cancer probabilities (observed risks). Vertical 
bars represent 95% confidence intervals for observed risks (54). 
In almost all covariate specific subgroups, BCRAT mean risks were significantly 
lower than the observed risks, while IBIS risks showed generally good agreement 
with observed risks, even in the subgroups of women considered at average risk (for 
example, no family history of breast cancer, BRCA1/2 mutation negative). 
A further useful measure of a model´s ability to discriminate for individual breast 
cancer cases is provided by the percentile of its assigned risk in the distribution for 
all non-cases, which we call its case risk percentile (CRP) (48). Figure 5 shows a 
scatterplot of BRCAT and IBIS models’ CRPs for 83 women who developed breast 
cancer 10 years within 10 years of risk assignment. Points above the diagonal line 
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(n=46) represent cases who were better identified by the IBIS than the BCRAT 
model, while points below the line (n=37) were better identified by the BCRAT than 
the IBIS model. The mean CRP across cases for a model is its area under the curve 
(AUC). Using the Wilcoxon signed rank test, we also found that the median IBIS 
CRP was statistically significantly different than that of BCRAT model (P value 0.04). 
 
Figure 5: Scatterplot of the case risk percentiles (CRPs). The horizontal and vertical coordinates of points give 
the BCRAT and IBIS CRPs, respectively, for the 83 breast cancer cases (54).  
Further, the discrimination was better for the IBIS model in almost all covariate 
specific subgroups, except for women who had a prior biopsy where the 
discrimination was better for the BCRAT model.  
Thus, the IBIS model, developed using extended family history and genetic data, 
also performs well in women considered at average risk (e.g. no family history, 
BRCA 1/2 mutation negative). These findings question the common clinical practice 
of applying risk models based on “a priori” assumptions of risks defined only by 
family history and genetic status (54).  
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Clinical guidelines for intensive surveillance including MRI screening involve 
estimates of remaining lifetime risk (RLR); in the USA, women with a RLR of 20% or 
higher meet “high risk” criteria for MRI screening. However, the clinical guidelines 
do not recommend which risk model to use; model predictions can differ depending 
on the risk factors they include and whether or not they consider the competing risk 
of death. In this study, we compare the risk models International Breast Cancer 
Intervention Study (IBIS) (67) and Breast and Ovarian Analysis of Disease Incidence 
and Carrier Estimation Algorithm (BOADICEA) (5, 6), which are both commonly used 
in clinical practice to identify women eligible for MRI screening according to the 
National Comprehensive Cancer Network (NCCN) guidelines (8) and have so far 
never been compared for USA women at high risk. Therefore using a cohort of high 
risk women from New York City (NYC), we compared several measures of calibration 
and discrimination of the IBIS and BOADICEA models (53). 
The models classified different proportions of women as high risk (IBIS=59.3% vs 
BOADICEA=20.1%) using the RLR threshold of 20% (Table 1). Thus, if one wants 
to perform more MRIs, it seems that one should use the IBIS model. However, using 
the 10-year threshold of 3.34%, the difference was smaller (IBIS=52.9% vs 
BOADICEA=43.2%) (Table 1). These differences could in part be because of the 
higher RLR upper age bound used by the IBIS (85 years) compared with the 
BOADICEA (80 years) model. We found the discordance was less when we defined 
high risk by a 10-year risk of 3.34% of higher (which is roughly equivalent to the 
NCCN 5-year risk of 1.67% (8)) (53). 
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Table 1: Classification of 1764 study subjects into high and low risk groups by the IBIS and BOADICEA models, 
using remaining lifetime risk and 10-year risk thresholds (53). 
 
IBIS risks (mean=4.9%) were better calibrated to observed breast cancer incidence 
(5.2%, 95% confidence interval (CI) = 4.2% to 6.4%) than were those of BOADICEA 
(mean=3.7%) overall and with quartiles of model risk (P value 0.20 by IBIS and P 
value 0.07 by BOADICEA). Both models gave similar discrimination, with area under 
the curves (AUC) of 0.67 (95% CI=0.61 to 0.73) using IBIS and 0.68 (95% CI=0.62 
to 0.74) using BOADICEA models (53).  
To supplement the AUC based comparison of IBIS and BOADICEA models’ 
discrimination, we also compared the IBIS and BOADICEA models’ case risk 
percentiles (48) of the 79 women who developed breast cancer within 10 years of 
recruitment. The vertical dashed line gives the threshold corresponding to 80% 
specificity for the BOADICEA model, while the horizontal dashed line gives the 
corresponding 80% specificity threshold for the IBIS model. The Figure 6 shows that 
seven cases were correctly deemed high risk by the IBIS but not by the BOADICEA 
model, while four cases were correctly identified as high risk by the BOADICEA but 
not by the IBIS model. This comparison gives a sensitivity of 33 of 79, or 41.8% for 
the IBIS model, and of 30 of 79, or 38.0% for the BOADICEA model (53). 
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Figure 6: Percentiles of 10-year case patients as measured by IBIS vs BOADICEA in the distribution of control 
patients risks (53).  
Our research showed that clinical guidelines based on RLR for high risk women are 
limited by discordance between commonly used risk models. Guidelines based on 
short term risks would be more useful, as models are generally developed and 
validated under a short time horizon (<10 years). Nevertheless, both IBIS and 
BOADICEA models still underestimated 10-year breast cancer risks in our cohort, 
with the discrepancies larger for BOADICEA than the IBIS model. The data suggest 
that the improved IBIS calibration reflects its inclusion of non-genetic risk factors 
(53). 
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Impact of modifiable risk factors on breast cancer risk 
Breast cancer is caused by a complex interplay of many genetic and non genetic 
risk factors. Therefore, the choice of a particular prediction model is an important 
aspect of clinical counseling. Further, many modifiable risk factors, such as physical 
activity and alcohol intake, are not included in current risk assement tools. Thus, 
integration of risk reduction strategies based on modifiable factors is limited to the 
modifiable factors present in a given risk model.  
 
Body mass index (BMI) is one of the few modifiable risk factors included in the IBIS 
model (67). To illustrate the potential impact of risk factor modification in model 
based risk assessment, we evaluated the IBIS model with and without BMI, for 
predicting future breast cancer occurrence in a prospective cohort of 665 
postmenopausal women (51). We focused on the role of BMI in postmenopausal 
women because of its positive association with breast cancer risk among 
postmenopausal, but not premenopausal women (12, 68). 
For each of 665 postmenopausal women we calculated the 10-year risks as assigned 
by the IBIS model with and without inclusion of the BMI (Figure 7). Overall, the 
accuracy of the IBIS model (overall agreement between observed and assigned 
risks) and discrimination (AUC concordance between assigned risks and outcomes) 
were similar with and without the BMI. In women with BMI > 25 kg/m2, adding the 
BMI improved discrimination (AUC=63.9% and 61.4% with and without BMI, P value 
>0.001). Using the commonly used 3.4% threshold for high risk status, the addition 
of the BMI reclassified 11 women from low to high risk, and 11 women from high to 
low risk (51).  
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Figure 7: Scatterplot of 10-year risks with and without BMI in model. Points denote 10-year risks for 665 
postmenopausal women as assigned by IBIS model with and without self-reported BMI (51).  
Further, we also analyzed the BMI´s influence on IBIS´10 year risk for five 
hypothetical women aged 50 years with varying levels of hereditary risk, keeping all 
other factors constant. For each woman, we examined the difference between her 
IBIS model risk with BMI of 27 versus 21 kg/m2 in terms of number of affected first-
degree relatives and BRCA1 mutation carrier status. Table 2 shows that this 
difference increases with a woman´s hereditary risk, ranging from 0.3% for women 
without affected relatives or BRCA1 mutation to 4.5% for those with three affected 
relatives and a BRCA1 mutation. This contrast shows that a woman at high 
hereditary risk can move across the 10-year threshold of 3.4% used to increase 
screening strategies by increasing her BMI. Moreover, obese women classified as 
high risk (i.e. as having ≥3.4% 10-year risk) could be reclassified as low risk by 
changing BMI alone, although this would require large weight reduction (51). 
Table 2: Effects of including BMI in IBIS model according to inherited risk factors (51). 
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More generally, this argument indicates that even when risk factors have limited 
impact at a population level, they can have a large impact on how an individual is 
classified into categories affecting their screening and chemoprevention counseling. 
We recommend that women be informed about both absolute and relative risk 
reductions when counseled for breast cancer prevention (51). 
 
As a potentially modifiable risk factor, 25-hydroxyvitamin D [25(OH)D] has become 
a major topic in cancer research (16). The question is whether vitamin D is protective 
against cancer. To date, only a few prospective studies have examined the 
relationship between serum 25(OH)D concentration and total cancer risk. We 
designed a population-based prospective cohort study to test the association 
between serum 25(OH)D concentration and the development of any cancer as well 
as specific common cancer types. The individuals for the present study were 
selected from the participants of the KORA (Cooperative Health Research in the 
Region of Augsburg) study (33, 74). We analysed data from the KORA cohort study 
including 2,003 initially cancer-free participants with baseline serum 25(OH)D 
measurements. We identified 69 participants who developed cancer during the 7-
year follow up period (5.4 cases per 1000 person year). The most common cancers 
were prostate (2.9 cases per 1000 person year), breast (2.5 cases per 1000 person 
year) and colorectal cancer (0.8 cases per 1000 person year) (11). 
We used Cox proportional hazard models to assess the association between 
25(OH)D levels and incident cancer risk (Table 3). Overall, we observed no 
significant relationship between serum 25(OH)D levels and cancer risk. The hazard 
ratio (HR) [95% CI] per 1 ng/ml increase in 25 (OH)D for this relationship was 1.00 
[0.97-1.04] adjusting for age, sex, BMI, and season of blood draw. This was also 
true in subgroup analysis for prostate cancer (HR 0.95 [0.88-1.03]), breast cancer 
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(HR [95% CI] 1.03 [0.97-1.09]), and colorectal cancer (HR [95% CI] 0.97 [0.88-1.07]) 
(11).  
Table 3: Hazard ratios for risk of developing cancer according to the baseline serum 25 (OH) D levels (11). 
 
However, the mean serum 25(OH)D concentrations were well below levels 
recommended by the Endocrine Society (20-30 ng/ml) for both the cases and non-
cases (Figure 8) (32). 
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Figure 8: Distribution of serum 25-hydroxyvitamin D (25(OH)D) concentration in the study population. The cut-off 
for defining vitamin D deficiency (20ng/ml) is indicated by the arrow.  
The prevalence of 25(OH)D sufficiency was low, as described previously (56). Our 
study found no protective effect of 25(OH)D against developing cancer. However, 
studies with more participants and additional measurements of 25(OH)D are still 
needed accurately clarify the relationship between 25(OH)D and total cancer risk 
(11). 
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Economic evaluation of risk adapted screening 
Because of the high costs involved in cancer screening and treatment, cost 
effectiveness is a key point in new strategies for individualized prevention. 
Mammography screening is the only cancer detection program in Germany that 
meets European Union (EU) directives entailing systematic invitation and quality 
assurance monitoring (2, 30). However, recent findings indicate that the cost 
effectiveness of current national screening programs could be improved (49). 
Screening procedures, such as mammography, require an expensive medical 
infrastructure, which entail both potential benefit and harm to participants. A more 
focused view on the individual risk for cancer may motivate individuals with high risk 
to use screening opportunities while reducing false positive findings and alleviating 
concerns of individuals at lower risk. A risk based approach would therefore allocate 
expensive screening resources to those who benefit the most from it.  
 
Individualized breast cancer screening has so far been economically evaluated 
under the assumption of full screening adherence. However, participation in breast 
cancer screening programs is low, especially in the EU (average 53.5%) (3). These 
levels do not reach the EU benchmark of acceptable participation (>70%) for 
effectiveness in the reduction of mortality (3, 24). There is scientific evidence to 
support that screening adherence is influenced by a woman’s perceived risk (28, 39, 
46). Decision analytical modelling is a very useful tool to balance benefits and harms 
of screening under a variety of circumstances. Recent studies have already taken 
up the challenge to weigh the balances of individualized screening (43, 60, 62, 66, 
70). However, these simulation models so far have not incorporated adherence into 
the decision analysis. This is the first study to identify three different risk adherence 
associations and to incorporate screening adherence into the economic evaluation 
of individualized mammography screening (7). In this study we base our simulations 
on a validated Markov transition model (60), which allows the integration of 
nonadherence. Figure 9 shows the state transition via the health states. The Markov 
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model assumes that healthy women may develop invasive breast cancer, ductal 
carcinoma in situ (DCIS) or die of other causes. Depending on the cancer stage at 
diagnosis, local, regional or distant, the time spent in this health state before death 
from breast cancer or from other causes is determined (7). 
 
Figure 9: State transition model (7).  
We assess mammography screening strategies for women aged between 50 and 74 
years. In our model, women have a combination of three risk factors (breast density, 
previous biopsy, family history). 
We use a micro-simulation approach to simulate individual women with combinations 
of the three risk factors. Simulations run from a start age of 50, until the end of their 
life or 100 years. 
Three adherence scenarios describing the relationship between risk and adherence 
were identified: 1) a positive association between risk and screening adherence, 2) 
a negative association or 3) a curvilinear relation relationship.  
Further, these three adherence scenarios were evaluated in three individualized 
strategies which were identified from the literature with stratified screening intervals 
based on the combination of the three risk factors: 1) Schosboe et al (SK) (60), 2 
Vilaprinyo et al (VF) (69) and 3) Trentham-Dietz et al (TDK) (66). 
Figure 10 describes the three individualized strategies (SK, VF, TDK) which differ in 
the recommended screening intervals (annual, biennial, or triennial) based on age 
group and a combination of three risk factors (breast density, previous biopsy, family 
history) (7). 
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Figure 10: Individualized strategies, intervals and population share (7). 
In a univariate sensitivity analysis (Figure 11), changing the screening adherence 
(in steps of 100%, 90%, 80%, 72.4%, and 60%) affects effectiveness and costs. TDK 
and SK produce very similar results, with only nonsignificant differences. Routine 
biennial screening produces the highest effect at highest cost, and VF produces 
significantly less effect at lower cost. When comparing the individualized strategies, 
SK and TDK, to routine screening, it is important to consider the adherence level 
and the risk adherence relationship. For adherence level above 90%, SK is almost 
certain to produce fewer QALYs than routine screening. For lower adherence levels 
and especially positive or curvilinear relationships, the differences SK and routine 
screening are statistically nonsignificant. Similarly, TDK is statistically significantly 
less effective then routine screening only if adherence levels are above 72%. For 
lower adherence and especially positive or curvilinear adherence, the differences 
between TDK and routine screening are statistically nonsignificant (7).  
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Figure 11: Cost effectiveness plane, adherence variations (7). 
Thus, our results show that the evaluation of individualized screening strategies 
compared with routine screening is dependent on the nature of the adherence level 
and the adherence rate (7). All three individualized strategies were designed as 
cheaper alternatives to routine screening. Under certain adherence conditions, 
individualized screening strategies may perform similarly well to routine screening, 
but save cost. Our results show that risk-stratified strategies are more attractive if 
high-risk groups are more likely to adhere (positive adherence).  
In conclusion, we show that “nonadherence” affects the relative performance of 
screening strategies. Thus, it is necessary to include the true adherence level to 
evaluate individualized screening strategies to select the best strategy (7). 
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Translating risk adapted screening into clinical practice 
The current Mammography Screening Program (Mammography Screening 1.0) has 
been the subject of criticism for some time (26, 35, 37). Invitation to take part is 
currently based on the risk factors of age and female sex, whereby women with an 
above average risk are screened too seldom and women with a low risk are possibly 
screened too often. Ultimately, the vision is to translate a risk adapted screening 
approach (Mammography Screening 2.0) into clinical practice by focusing screening 
efforts on those individuals who are most likely to develop cancer (18). 
 
In Mammography Screening 2.0 dealing with the risk models represents an 
additional challenge (55). This is where our current research project 
RISIKOLOTSE.DE comes in. An online platform will be generated which provides 
information and tools that will allow the breast cancer risk to be calculated, 
understood and evaluated. The target groups are doctors and laypersons: doctors 
will be supported in risk communication and counseling, laypersons in weighing the 
benefits and risks of taking part. The decision-making process for participation will 
be facilitated thereby. As an initial assessment of the demand for this project we 
organized a focus group with 15 physicians and representatives of the health 
service. The discussion was analyzed with qualitative methods (18, 45).  
As an introduction, two brief cases were presented (Figure 12). The experts were to 
decide whether they would advise the women for or against mammography. For the 
42-year old woman in case 1, whose cousin had breast cancer, despite an increased 
breast cancer risk, there was no clear advice. In contrast, nearly all of them advised 
the 51-year old woman in case 2, with average breast cancer risk, to take part in the 
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mammography screening. The two case examples show were the weakness of the 
current mammography screening lie. The invitation is currently based on the age of 
women between 50 and 69 years. This screening recommendation appears to 
represent a binding guideline for doctors. On the other hand, there is no uniform 
recommendation on mammography for women under 50 years. However, individual 
risk calculation for the IBIS model risk calculation procedure, which includes other 
risk factors, results in an increased breast cancer risk for 42-year old woman and 
an average risk for the 51-year old compared with the general population. 
Nevertheless, only the 51-year old is included in the screening program according 
to the current standards (18). 
 
Figure 12: Voting result of the case examples (18). 
The participants admitted that when counseling about breast cancer screening they 
would emphasize positive aspects over negative aspects. General practitioners in 
particular reported that they are confronted “really often” with questions about the 
current mammography screening. The physicians were uncertain whether they were 
competent enough for counseling and were self-critical, e.g.“ It is often the case that 
the women but also the doctors don´t understand it.” (gynecologist) or „ “I am already 
a bit uncertain because I originally thought that screening can really only be good 
(..) But it is not quite so simple.“ (general practitioner). 
The concept of individualized risk adapted screening was assessed positively overall 
by the participants. The limitation in MammographyScreening 1.0 to the risk factors 
age and sex was criticized unanimously: “We do know that that doesn´t suffice” 
(gynecologist) Thus, “mammograms are done in women who derive no benefit from 
them” (gynecologist). In this connection, the financial aspects for the health care 
system were also addressed: “Because of limited resources, it must be considered 
(…) whether it is actually necessary for us to screen all women” (public health 
service). 
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The participants were in agreement that only physicians should interpret the results 
of the risk calculation: “The (medical) interpretation is always needed” 
(gynaecologist). Concerns were raised, if laymen would use risk calculators by 
themselves: “You only need to imagine a woman with a family history (…), who keeps 
on clicking, forgets something and lands at a supposedly low risk and tells herself: 
everything´s OK ” (gynecologist). Possible positive aspects of independent use of 
risk calculators by lay persons (empowerment) were not mentioned by the 
participants. 
The biggest challenge for the implementation is the lack of time and the complexity 
of risk communication, which would overtax many doctors. Counseling about the 
results of an individualised risk calculation is even more challenging: “I must classify 
the risk and we already see from genetics, that that is not so simple.” 
(gynaecologist). The objection was made that doctors could learn these 
competencies: “I find that every doctor must be able to handle the subject of risk 
communication” (gynaecologist). 
The experts from the focus group approved the idea of risk adapted screening 
(Mammography Screening 2.0). “I think there are women who have such a low risk 
that they need less or no screening” (radiologist). On the other hand, women with 
an increased risk would benefit from earlier, more frequent, or longer participation, 
and from additional investigations such as ultrasonography or MR imaging. 
Mammography Screening 2.0 could thus lead to “provision of better care for the 
overall population, (…) by simply redistributing them [=resources]” (radiologist).  
Overall, the suggestions and new ideas from the focus group ranged from 
administrative and regulatory changes to new forms of counselling and adaptable 
practice aids. An important indicator for the RISIKOLOTSE.DE conception and for 
planning future surveys was that risk calculation for Mammography Screening 2.0 
was regarded as purely medical function and that the concept of participatory 
decision making played hardly any part in the discussion (18).  
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Discussion 
Breast cancer is one of the most important public health concerns, as it is the most 
common cancer, and also the most common cause of cancer death, among women 
(1). The incidence of breast cancer has risen in the last decades due to changes in 
lifestyle, reproduction and diet. Because of demographic ageing, it will be an even 
more important health issue in the future (52). It has been estimated that around 
30% of all breast cancers are attributable to modifiable factors (e.g. excess body 
weight, physical inactivity and alcohol intake) (38). Even though there is enormous 
potential to reduce the burden of disease in the general population by primary 
prevention, the majority of cancer cases cannot be avoided (76). Therefore, 
secondary prevention by means of screening and early treatment appears important, 
and there has been strong interest in implementing screening strategies that will 
detect early breast cancer, thereby reducing mortality (2).  
Approximately Ten years after successfully introduction in Germany in 2005 of a 
systematic population-based Mammography Screening Program, many 
controversies have arisen (26, 36, 37, 72). In particular on the benefit of screening, 
in terms of whether the benefit of reduced breast cancer mortality, outweighs the 
harm caused by over diagnosis of cancers detected at screening that would not have 
been detected during the woman’s lifetime, as well as unnecessary diagnostic 
procedures involving radiation (26, 36, 37, 72). The Cochrane Review concluded 
that, for every 2000 women invited for screening over a period of 10 years, one will 
be saved from cancer-related death but 10 will be over diagnosed (27). The Swiss 
Medical Board’s report 2014 concluded that “no new systematic Mammography 
Screening Program be introduced and that a time limit be placed on existing 
programs” (10). 
All of this raises the need to re-think current mammography screening programs e.g. 
Mammography Screening 1.0. Is it appropriate to perform screening in every woman 
aged 50-69 years, or should uniform population screening be replaced or 
complemented with an individualized screening approach: such as Mammography 
Screening 2.0 (13)? In light of the recent emergence of more accurate risk prediction 
tools and the fact that trade-offs between risks and benefits may vary on the 
individual level, an individualized program is likely to represent a more effective 
approach than population-wide screening. However, an individualized screening 
strategy faces new challenges, such as (i) how to calculate, (ii) how to evaluate and 
(iii) how to communicate (55).  
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My research has addressed ways of translating risk adapted screening into clinical 
practice.  
How to calculate? 
A basic requirement for risk adapted screening is an accurate assessment of a 
woman´s absolute breast cancer risk. Therefore, the choice of a particular prediction 
model is an important aspect of individualized screening and surveillance (53, 54) . 
So far clinicians use different breast cancer risk models for women considered at 
average and above average risk, based largely on their family histories and genetic 
factors. However, oncologists and genetic counsellors would be well served by a 
single model that avoids having to choose among several models on the basis of 
patient characteristics (54). 
To address this question, we compared different breast cancer risk assessment tools 
in a longitudinal NYC cohort (54). In summary, we found that the IBIS model 
surpassed the BCRAT model in this cohort whose risks span the continuum of breast 
cancer risk. This was true in subgroups containing women typically considered to be 
of average risk (for example, no family history of breast cancer, BRCA1/2 negative). 
We could show that a risk model that has been developed based on extended family 
history and genetic data, such as the IBIS model, also performs well in women 
considered at average risk (54). Further, we could show that IBIS and BOADICEA 
models were both well calibrated, even though IBIS performed slightly better. Both 
models gave similar discrimination, with area under the curve of 0.67 using IBIS and 
0.68 using BOADICEA (53).  
A limitation to our study is that our validation study and other validation studies have 
been conducted with small numbers (4, 41, 50, 53, 54). There is a need for much 
larger studies in high risk populations and in the general population (23).  
However, we could show that currently used risk models, such as IBIS and 
BOADICEA, are well calibrated and conclusively - with an AUC almost 0.7 - already 
provide a useful perspective for individualized screening as they perform better than 
considering age alone (23). 
How to evaluate? 
Our ultimate goal is to categorize women according to their risk of breast cancer as 
accurately as possible, based on their profile of genetic and non-genetic risk factors, 
and to recommend a more individualized screening program. However, at the 
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moment we do not have an international agreement how best to define the “high 
risk” group.  
The NCCN guidelines (8) recommend that high risk women consider risk reduction 
strategies and annual MRI starting at the age of 30 years. The NCCN definition of 
high risk includes women who have a RLR of 20%. However, it is not specified which 
risk model to use. We found that the life time risks assigned by IBIS or BOADICEA 
differ substantially and thus the models classified different proportions of women as 
high risk: 60% when using IBIS compared to 20% using the BOADICEA. Thus, if one 
wants to perform more MRIs, it seems that one should use the IBIS model. 
A further challenge for risk adapted screening is that clinical guidelines for breast 
cancer chemoprevention and MRI screening involve estimates of RLR. We found 
that implementing these RLR-based guidelines is problematic for two reasons (53). 
First, the models disagree on the definition of a woman´s RLR with the IBIS model 
using age 85 years and the BOADICEA model using age 80 years. We found that 
the RLRs assigned by the IBIS and BOADICEA models differ substantially and that 
these differences were reduced when comparing the models’ predicted 10-year 
risks. Second, it is not feasible to assess model RLR predictions, because we cannot 
observe breast cancer outcomes during the remaining lifetimes of cohort subjects. 
In fact, risk models are generally developed and validated over a fixed horizon (e.g. 
five or ten years of follow-up), making estimates of RLR less precise (53).  
Thus, a greater recognition of the limitation of RLRs estimates is needed. Increased 
clinical use of shorter fixed time horizons when conveying risk, may be particularly 
important in order to improve the validity of risk assessment. We recommend that 
physicians use time periods of briefer duration, such as 5- or 10-year risks (53).  
How to communicate 
It is apparent in the literature that communication in the framework of Mammography 
Screening 1.0 is already a challenge. Women should be enabled to make an 
informed decision (64). The informed consent assumes that benefits and risks of 
screening are understood, correctly interpreted and applied to their own situation. A 
requirement for the health competence or health literacy is a basic understanding of 
statistics. However the reality is, that statistical statements about positive and 
negative effects of screening are often misinterpreted by both doctors and by 
laypersons seeking advice (71). The benefit is sometimes massively overestimated 
while the risks are rather trivialized (31). In the future Mammography Screening 2.0 
dealing with the risk models may present an additional challenge. Many doctors 
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assume in general that they already practice joint decision-making. Studies suggest 
that the assessment is deceptive and that there is a perception–reality gap (65). 
Results from our focus group showed that the experts emphasized that risk 
calculation in particular should be reserved to doctors; lay persons were not trusted 
by the majority to be able to take responsibility for this. The biggest challenge for 
the implementation is the complexity of risk communication, as counseling about the 
results of an individualized risk calculation is more challenging (18).  
Overall, the experts form the focus group approved the idea of risk adapted 
screening. However, there is a need to implement participatory decision-making in 
routine medical practice, and also a need for fundamental schemes for risk 
communication (18).  
Conclusion  
Although the current Mammography Screening 1.0 is mainly age dependent, there 
are already target groups in Germany, for which risk-adapted screening has been 
implemented (40). Currently, indisputably women who carry a mutation in a known 
cancer gene, have access to an intensified surveillance program (59). Access to 
intensified surveillance is more controversial for women where the decision is based 
on the calculated risk (heterozygous risk >20% or lifetime risk > 30%) based on 
Cyrillic (59). This risk calculation method is outdated and needs to be revised (55). 
However, changing the risk calculation method facilitates a big challenge for the 
German Consortium of Hereditary Breast and Ovarian Cancer (55). The target group 
which will have access to intensified surveillance will change and we need to 
communicate the changes in decision rules to our patients. Some women will “no 
longer have an increased risk” and can be discharged from intensified surveillance. 
Other women will “have an increased risk” and suddenly have access to intensified 
surveillance. However, the goal is to improve the efficiency of the intensified 
surveillance program. Therefore, it is very important to evaluate the outcome 
regularly and also to evaluate the results economically (55). 
There is a need for fundamental schemes for risk communication and also to develop 
practical counseling aids. This is where the RISIKOLOTSE.DE project comes in 
(Figure 13). We are planning to develop an online platform which will provide 
information and tools that will allow the breast cancer risk to be calculated, 
understood and evaluated (18). 
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Figure 13: RISIKOLOTSE.DE (18). 
 
In conclusion our research shows that an individualized risk adapted screening 
strategy is feasible and of advantage in clinical practice. Our research could 
contribute to the evidence required to overcome any barriers associated with 
replacing the current screening guidelines with a more focused individualized 
approach, which requires medical counseling. It forms the basis for guidance 
required by political and funding institutions to assess the cost/benefit of 
implementing Mammography Screening 2.0 as an alternative to the current “all 
inclusive” age related screening guidelines. 
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Abstract 
There has been a lot of controversy about the current mammography screening 
program. Screening recommendations for breast cancer in Germany are currently 
based solely on age and gender of an individual, despite the fact that additional 
genetic and non-genetic factors are known to influence cancer risk. Recent breast 
cancer risk models include these factors. They would allow the implication of a risk 
adapted screening approach, “Mammography Screening 2.0”. On the one hand there 
is a need to intensify diagnostic procedures for women at higher risk; on the other 
hand it is desired to avoid unnecessary diagnostic procedures in women who are 
unlikely to develop breast cancer. The aim is to improve the efficiency of the 
screening program and to help guide screening decisions by patients’ individual risk 
profiles and preferences.  
However, the implementation of such a strategy faces new challenges, such as the 
choice of the adequate prediction model, the interpretation of the results, and the 
ways to communicate the risks. 
We could show that currently used risk models, such as IBIS and BOADICEA, are 
well calibrated and conclusively already provide a useful perspective for 
individualized screening as they perform more effectively than considering age 
alone. Our ultimate goal is to categorize women according to their risk of breast 
cancer as accurately as possible, based on their profile of genetic and non-genetic 
risk factors, and to recommend a more individualized screening program. However, 
at the moment we do not have an international agreement how best to define for 
breast cancer the “high risk” group. We recommend that physicians use time periods 
of briefer duration, such as 5 or 10-year risks to identify women at high risk. 
Appropriate risk communication in Mammography Screening 2.0 will present a new 
but interesting challenge for physicians. There is a need to implement shared 
decision-making in routine medical practice, and also a need for fundamental 
schemes for risk communication.  
In conclusion our research shows that an individualized risk adapted screening 
strategy is feasible and of advantage in clinical practice. Our research could 
contribute to the evidence required to overcome any barriers associated with 
replacing the current “all inclusive” age related screening guidelines with a more 
focused individualized approach, which requires medical counseling.    
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